Opinion of the President on the legitimacy of changes to the B.75 drug program
On 2 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued opinion No. BP.422.16.2024.MKS on the appropriateness of making changes to the B.75 drug program
Publication in Public Information Bulletin (BIP) >>